Overview

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in patients with Metastatic Colorectal Cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Mast Therapeutics, Inc.

Treatments:

Bevacizumab
Fluorouracil
Leucovorin
Tetrahydrofolates